Develops and commercializes therapeutics for cardiovascular health, particularly focusing on reducing residual cardiovascular risk.
Amarin Corporation plc is a pharmaceutical company specializing in the development and distribution of therapies aimed at treating cardiovascular diseases across several global markets including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Central to its portfolio is VASCEPA, a prescription omega-3 fatty acid product prescribed as an adjunct to diet for lowering triglyceride levels in adults with severe hypertriglyceridemia.
Primarily distributing its products through wholesalers and specialty pharmacy providers, Amarin Corporation plc maintains a strategic collaboration with Mochida Pharmaceutical Co., Ltd. This partnership focuses on the development and commercialization of drug products and indications based on VASCEPA's active pharmaceutical ingredient, eicosapentaenoic acid (EPA).
Originally established as Ethical Holdings plc and rebranded in 1999, Amarin Corporation plc has been a leader in cardiovascular therapeutics since its incorporation in 1989. Headquartered in Dublin, Ireland, the company continues to expand its global footprint while advancing innovative treatments that address significant medical needs in cardiovascular health.